ES3038078T3 - Histone acetylation writer inhibitor development and uses thereof - Google Patents

Histone acetylation writer inhibitor development and uses thereof

Info

Publication number
ES3038078T3
ES3038078T3 ES19878099T ES19878099T ES3038078T3 ES 3038078 T3 ES3038078 T3 ES 3038078T3 ES 19878099 T ES19878099 T ES 19878099T ES 19878099 T ES19878099 T ES 19878099T ES 3038078 T3 ES3038078 T3 ES 3038078T3
Authority
ES
Spain
Prior art keywords
group
cpd
cancer
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19878099T
Other languages
English (en)
Spanish (es)
Inventor
Jun Qi
Adam D Durbin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES3038078T3 publication Critical patent/ES3038078T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
ES19878099T 2018-11-02 2019-11-01 Histone acetylation writer inhibitor development and uses thereof Active ES3038078T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754934P 2018-11-02 2018-11-02
PCT/US2019/059401 WO2020092907A1 (en) 2018-11-02 2019-11-01 Acetylation writer inhibitor development and uses thereof

Publications (1)

Publication Number Publication Date
ES3038078T3 true ES3038078T3 (en) 2025-10-09

Family

ID=70463920

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19878099T Active ES3038078T3 (en) 2018-11-02 2019-11-01 Histone acetylation writer inhibitor development and uses thereof

Country Status (8)

Country Link
US (2) US12428412B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873898B1 (cg-RX-API-DMAC7.html)
JP (1) JP7712867B2 (cg-RX-API-DMAC7.html)
CN (1) CN112969696B (cg-RX-API-DMAC7.html)
AU (1) AU2019371400B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118597A1 (cg-RX-API-DMAC7.html)
ES (1) ES3038078T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020092907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN111217802B (zh) * 2018-11-27 2021-10-08 海创药业股份有限公司 一类组蛋白乙酰化酶p300抑制剂及其用途
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
EP3986470A4 (en) * 2019-06-18 2023-10-04 Dana-Farber Cancer Institute, Inc. TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
AU2021316053A1 (en) 2020-07-30 2023-03-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
EP4304572A4 (en) * 2021-03-09 2025-02-12 Dana-Farber Cancer Institute, Inc. EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA
JP2024540080A (ja) 2021-10-29 2024-10-31 カイメラ セラピューティクス, インコーポレイテッド Irak4分解剤およびその合成
CN116375717B (zh) * 2021-12-30 2025-10-28 成都先导药物开发股份有限公司 螺环化合物及其双功能化合物和用途
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
GB202209404D0 (en) * 2022-06-27 2022-08-10 Univ Of Sussex Compounds
JP2025137900A (ja) * 2022-08-10 2025-09-25 住友ファーマ株式会社 第4級炭素で置換された3級アミド誘導体
JP7856847B2 (ja) * 2022-09-07 2026-05-11 成都先導薬物開発股▲フン▼有限公司 スピロ化合物及びその用途
CN119255996B (zh) * 2022-09-08 2026-04-24 成都先导药物开发股份有限公司 螺环化合物及其用途
WO2024064358A1 (en) * 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
CN116178339B (zh) * 2023-02-20 2024-08-06 杭州医学院 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用
GB202302941D0 (en) 2023-02-28 2023-04-12 Tocris Cookson Ltd Proteolysis-targeting chimeras
AU2024395784A1 (en) 2023-12-07 2026-06-11 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b
WO2026088071A1 (en) 2024-10-23 2026-04-30 Pfizer Inc. Substituted fused heteroaryl lactam compounds
WO2026154417A1 (en) 2025-01-17 2026-07-23 Pfizer Inc. Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity
WO2026159633A1 (en) 2025-01-24 2026-07-30 Pfizer Inc. 4-(2-(dimethylamino)-2-oxoethyl)-3-methyl-5-oxo-2,3,4,5-tetrahydrobenzofuro[2,3-f][1,4]oxazepine-3-carboxamide compounds and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US20160235716A1 (en) 2014-09-18 2016-08-18 Abbvie Inc. Spirocyclic hat inhibitors and methods for their use
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CN109562113A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
MX2019004950A (es) * 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3986470A4 (en) * 2019-06-18 2023-10-04 Dana-Farber Cancer Institute, Inc. TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES

Also Published As

Publication number Publication date
AU2019371400A1 (en) 2021-04-08
JP2022512900A (ja) 2022-02-07
CA3118597A1 (en) 2020-05-07
CN112969696A (zh) 2021-06-15
US20250333402A1 (en) 2025-10-30
WO2020092907A1 (en) 2020-05-07
US12428412B2 (en) 2025-09-30
AU2019371400B2 (en) 2024-10-17
EP3873898B1 (en) 2025-05-28
CN112969696B (zh) 2024-06-11
EP3873898A1 (en) 2021-09-08
US20220009916A1 (en) 2022-01-13
JP7712867B2 (ja) 2025-07-24
EP3873898A4 (en) 2022-11-30

Similar Documents

Publication Publication Date Title
US20250333402A1 (en) Acetylation writer inhibitor development and uses thereof
US20250388562A1 (en) Small molecule degraders of helios and methods of use
US11771697B2 (en) Small molecule degraders of polybromo-1 (PBRM1)
US20220177466A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
US20220040317A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
JP2022537521A (ja) 小分子標的ブロモ/アセチルタンパク質およびその使用
US20220387604A1 (en) Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof
US20220175722A1 (en) Degraders of fibroblast growth factor receptor 2 (fgfr2)
US20240246956A1 (en) Class iia histone deacetylase (hdac) degrader ligands and methods of use thereof
EP4460306A2 (en) Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)
US20230149551A1 (en) Arginine methyltransferase 5 (prmt5) degraders and uses thereof
KR20240088939A (ko) Dot1l 분해를 위한 소분자 및 이의 용도
WO2022140554A1 (en) Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof
HK40055968B (en) Histone acetylation writer inhibitor development and uses thereof
HK40055968A (en) Histone acetylation writer inhibitor development and uses thereof
US20240374737A1 (en) Erk5 degraders and uses thereof